Healthcare provider profile · identity verified

Ruilin Wang, MD

Family Practice · LINCOLN, NE · NPI 1518036433

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	510	130
Levothyroxine Sodium	Levothyroxine Sodium	448	88
Metoprolol Succinate	Metoprolol Succinate	376	92
Losartan Potassium	Losartan Potassium	365	97
Amlodipine Besylate	Amlodipine Besylate	354	93
Omeprazole	Omeprazole	172	40
Pantoprazole Sodium	Pantoprazole Sodium	168	34
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	153	23
Lisinopril	Lisinopril	150	40
Tramadol Hcl	Tramadol Hcl	141	37
Gabapentin	Gabapentin	135	41
Potassium Chloride	Potassium Chloride	134	37
Escitalopram Oxalate	Escitalopram Oxalate	129	31
Eliquis	Apixaban	127	20
Simvastatin	Simvastatin	126	29
Alprazolam	Alprazolam	113	31
Zolpidem Tartrate	Zolpidem Tartrate	109	24
Hydrochlorothiazide	Hydrochlorothiazide	106	39
Ropinirole Hcl	Ropinirole Hcl	106	13
Duloxetine Hcl	Duloxetine Hcl	105	22
Rosuvastatin Calcium	Rosuvastatin Calcium	104	33
Albuterol Sulfate Hfa	Albuterol Sulfate	103	52
Furosemide	Furosemide	102	29
Meloxicam	Meloxicam	91	27
Metformin Hcl Er	Metformin Hcl	87	23
Fenofibrate	Fenofibrate Nanocrystallized	85	17
Metoprolol Tartrate	Metoprolol Tartrate	82	suppressed
Pregabalin	Pregabalin	80	17
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	68	16
Memantine Hcl	Memantine Hcl	63	suppressed
Synthroid	Levothyroxine Sodium	62	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	61	28
Trazodone Hcl	Trazodone Hcl	60	suppressed
Allopurinol	Allopurinol	58	20
Sertraline Hcl	Sertraline Hcl	58	15
Clonazepam	Clonazepam	57	suppressed
Sucralfate	Sucralfate	57	suppressed
Spironolactone	Spironolactone	56	17
Clopidogrel	Clopidogrel Bisulfate	55	12
Montelukast Sodium	Montelukast Sodium	54	12
Tamsulosin Hcl	Tamsulosin Hcl	54	suppressed
Ibandronate Sodium	Ibandronate Sodium	53	15
Buspirone Hcl	Buspirone Hcl	52	12
Ozempic	Semaglutide	52	suppressed
Methenamine Hippurate	Methenamine Hippurate	50	suppressed
Donepezil Hcl	Donepezil Hcl	48	suppressed
Xarelto	Rivaroxaban	47	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	46	26
Lorazepam	Lorazepam	45	14
Valacyclovir	Valacyclovir Hcl	44	12
Fluticasone Propionate	Fluticasone Propionate	42	15
Azithromycin	Azithromycin	40	26
Citalopram Hbr	Citalopram Hydrobromide	40	suppressed
Lamotrigine	Lamotrigine	40	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	40	suppressed
Warfarin Sodium	Warfarin Sodium	40	suppressed
Carvedilol	Carvedilol	39	suppressed
Torsemide	Torsemide	39	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	37	17
Diazepam	Diazepam	37	suppressed
Metformin Hcl	Metformin Hcl	36	11
Loperamide	Loperamide Hcl	34	suppressed
Ondansetron Hcl	Ondansetron Hcl	34	13
Dicyclomine Hcl	Dicyclomine Hcl	33	15
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	33	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	33	suppressed
Bupropion Xl	Bupropion Hcl	32	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	32	suppressed
Ondansetron Odt	Ondansetron	32	14
Pravastatin Sodium	Pravastatin Sodium	31	suppressed
Methocarbamol	Methocarbamol	29	suppressed
Famotidine	Famotidine	28	suppressed
Meclizine Hcl	Meclizine Hcl	28	12
Mirtazapine	Mirtazapine	28	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	27	suppressed
Jardiance	Empagliflozin	26	suppressed
Tizanidine Hcl	Tizanidine Hcl	26	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	25	14
Bisoprolol Fumarate	Bisoprolol Fumarate	24	suppressed
Rizatriptan	Rizatriptan Benzoate	24	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	24	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	24	suppressed
Alendronate Sodium	Alendronate Sodium	23	11
Cefdinir	Cefdinir	23	22
Methylprednisolone	Methylprednisolone	23	19
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	22	12
Nortriptyline Hcl	Nortriptyline Hcl	22	suppressed
Solifenacin Succinate	Solifenacin Succinate	22	suppressed
Spiriva Handihaler	Tiotropium Bromide	22	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	22	suppressed
Ventolin Hfa	Albuterol Sulfate	22	suppressed
Farxiga	Dapagliflozin Propanediol	21	suppressed
Benazepril Hcl	Benazepril Hcl	20	suppressed
Doxepin Hcl	Doxepin Hcl	20	suppressed
Fenofibrate	Fenofibrate,micronized	19	suppressed
Amoxicillin	Amoxicillin	18	13
Atenolol	Atenolol	18	suppressed
Januvia	Sitagliptin Phosphate	18	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	18	suppressed
Carisoprodol	Carisoprodol	17	suppressed
Clonidine Hcl	Clonidine Hcl	17	suppressed
Estradiol	Estradiol	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	17	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	16	suppressed
Dexlansoprazole Dr	Dexlansoprazole	16	suppressed
Ezetimibe	Ezetimibe	16	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	16	suppressed
Nebivolol Hcl	Nebivolol Hcl	16	suppressed
Risperidone	Risperidone	16	suppressed
Topiramate	Topiramate	16	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	16	suppressed
Mounjaro	Tirzepatide	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	14	suppressed
Cephalexin	Cephalexin	14	12
Desmopressin Acetate	Desmopressin Acetate	14	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	14	suppressed
Aimovig Autoinjector	Erenumab-Aooe	13	suppressed
Bupropion Hcl	Bupropion Hcl	13	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Dorzolamide-Timolol	Dorzolamide/Timolol/Pf	12	suppressed
Ethosuximide	Ethosuximide	12	suppressed
Klor-Con M20	Potassium Chloride	12	suppressed
Tramadol Hcl Er	Tramadol Hcl	12	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	11	suppressed
Bevespi Aerosphere	Glycopyrrolate/Formoterol Fum	11	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Finasteride	Finasteride	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Mometasone Furoate	Mometasone Furoate	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error